Emicizumab

ATC Code B02BX06

Emicizumab

Definition

A humanized, immunoglobulin G4 (IgG4), bispecific monoclonal antibody against both the activated coagulation factor IX (FIXa) and factor X (FX) that can be used for the treatment of hemophilia A (HA). Upon administration, emicizumab targets and binds to both the FIXa and to FX, thereby bridging FIXa and FX, activating FX, and allowing for the activation and continuation of the coagulation cascade. FX is normally activated by coagulation factor VIII (FVIII); FVIII is missing in HA patients.

Also known as ACE 910, ACE-910, ACE910, EMICIZUMAB, Emicizumab-kxwh, Hemlibra, Immunoglobulin G4-kappa, Bispecific, Anti-(Homo sapiens F9a (Activated Coagulation Factor F9, Activated Coagulation Factor IX) and Anti-(Homo sapiens F10 (Coagulation Factor 10, Coagulation Factor X)), Humanized Monoclonal Antibody — per NCIT

Also identified as